Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [(68)Ga]Ga-DOTA-E-[c(RGDfK)](2) PET/CT
Publication year
2020Source
European Journal of Nuclear Medicine and Molecular Imaging, 47, 11, (2020), pp. 2647-2655ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Medical Imaging
Medical Oncology
Pathology
Radiation Oncology
Oral and Maxillofacial Surgery
Otorhinolaryngology
Journal title
European Journal of Nuclear Medicine and Molecular Imaging
Volume
vol. 47
Issue
iss. 11
Page start
p. 2647
Page end
p. 2655
Subject
Radboudumc 14: Tumours of the digestive tract RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 15: Urological cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences; Radboudumc 19: Nanomedicine RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life SciencesAbstract
PURPOSE: Angiogenesis plays an important role in the growth and metastatic spread of solid tumours and is characterised by the expression of integrins on the cell surface of endothelial cells. Radiolabelled RGD peptides specifically target angiogenesis-related α(v)β(3) integrins, expressed on the activated endothelial cells of sprouting blood vessels. Here, we validated the feasibility of (68)Ga[Ga]-DOTA-E-[c(RGDfK)](2) ((68)Ga-RGD) PET/CT to visualise angiogenesis in patients with oral squamous cell carcinoma (OSCC). METHODS: Ten patients with OSCC and scheduled for surgical resection including elective neck dissection received an intravenously administration of (68)Ga-RGD (42 ± 8 μg; 214 ± 9 MBq). All patients subsequently underwent dynamic (n = 5) or static PET/CT imaging (n = 5) for 60 min or for 4 min/bed position at 30, 60 and 90 min after injection, respectively. Quantitative tracer uptake in tumour lesions was expressed as standardised uptake values (SUV). Additionally, tumour tissue was immunohistochemically stained for α(v)β(3) integrin to assess the expression pattern. RESULTS: (68)Ga-RGD tumour accumulation was observed in all patients. At 60 min post injection, tumour SUV(max) ranged between 4.0 and 12.7. Tracer accumulation in tumour tissue plateaued at 10 min after injection. Uptake in background tissue did not change over time, resulting in tumour-to-muscle tissue of 6.4 ± 0.7 at 60 min post injection. CONCLUSIONS: (68)Ga-RGD PET/CT of α(v)β(3) integrin expression in OSCC patients is feasible with adequate tumour-to-background ratios. It will provide more insight in angiogenesis as a hallmark of the head and neck squamous cell carcinomas' tumour microenvironment. TRIAL REGISTRATION: https://eudract.ema.europa.eu no. 2015-000917-31.
This item appears in the following Collection(s)
- Academic publications [227881]
- Electronic publications [107344]
- Faculty of Medical Sciences [86219]
- Open Access publications [76465]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.